Key messages from scientific research that's ready to be acted on
Got It, Hide thisBrunstrom M, Carlberg B Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016 Feb 24;352:i717.
In people who have diabetes, what is the effect of blood pressure (BP)-lowering drugs when people start with different BP levels?
People with diabetes have a higher risk of cardiovascular disease and often also have high BP. High BP is usually defined as having a systolic BP of 140 mm Hg or more or a diastolic BP of 90 mm Hg or more. High BP often doesn’t cause symptoms, but over time it can cause strokes or heart problems, including heart attacks.
Drugs used to lower high BP can reduce risk of cardiovascular events, although they may work differently in people with mild high BP.
The researchers did a systematic review, searching for studies published up to February 2013. They found 49 randomized controlled trials with 73,738 people.
The key features of the trials were:
The researchers grouped the studies by the average systolic BP at the beginning of the trials.
Outcomes were death, cardiovascular death, heart attack, stroke, heart failure, and end-stage renal (kidney) disease.
When the average systolic BP was higher than 150 mm Hg at the beginning of the trial (before the trial treatment was started), BP-lowering drugs decreased all-cause death, cardiovascular death, heart attack, stroke, and end-stage renal (kidney) disease.
When the average systolic BP was between 140 and 150 mm Hg at the beginning of the trial, BP-lowering drugs decreased all-cause death, heart attack, and heart failure.
When the average systolic BP was less than 140 mm Hg, BP-lowering drugs showed a borderline increase in cardiovascular death and did not show differences for the other outcomes.
In people who have diabetes and systolic BP of 140 mm Hg or higher, BP-lowering drugs decrease death and heart attacks. In people with systolic blood pressure less than 140 mm Hg, BP-lowering drugs do not decrease death and may be linked to a higher risk of cardiovascular death.
Outcomes | Average systolic blood pressure (BP) at the beginning of the trials (before the start of treatment) | ||
| Systolic BP higher than 150 mm Hg | Systolic BP between 140 to 150 mm Hg | Systolic BP less than 140 mm Hg |
All-cause death | 1% to 20% decrease | 2% to 22% decrease | No difference |
Cardiovascular death | 1% to 43% decrease | No difference | 0% to 32% increase |
Heart attack | 13% to 37% decrease | 7% to 24% decrease | No difference |
Stroke | 9% to 35% decrease | No difference | No difference |
Heart failure | No difference | 3% to 34% decrease | No difference |
End-stage renal (kidney) disease | 6% to 29% decrease | No difference | No difference |
*Most trials compared BP-lowering drugs with placebo.